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Phosphorylation of the human AR (androgen receptor) is directly
correlated with the appearance of at least three AR isoforms on
an SDS/polyacrylamide gel. However, it is still not clear to what
extent phosphorylation is involved in the occurrence of isoforms,
which sites are phosphorylated and what are the functions of these
phosphosites. The human AR was expressed in COS-1 cells and
AR phosphorylation was studied further by mutational analyses
and by using reversed-phase HPLC and MS. The reversed-phase
HPLC elution pattern of the three isoforms revealed that Ser-650
was phosphorylated constitutively. After de novo synthesis, only
Ser-650 was phosphorylated in the smallest isoform of 110 kDa
and both Ser-650 and Ser-94 were phosphorylated in the second
isoform of 112 kDa. The hormone-induced 114 kDa isoform
shows an overall increase in phosphorylation of all the isolated
peptides. The activities of the Ser–Ala substitution mutant S650A
(Ser-650 → Ala) was found to be identical with wild-type AR
activation in four different cell lines and three different func-
tional analyses, e.g. transactivation, N- and C-terminal-domain
interaction and co-activation by transcriptional intermediary fac-
tor 2. This was also found for mutants S94A and S515A with re-
spect to transactivation. However, the S515A mutation, which
should eliminate phosphorylation of the potential mitogen-
activated protein kinase site, Ser-515, resulted in an unphos-
phorylated form of the peptide containing Ser-650. This suggests
that Ser-515 can modulate phosphorylation at another site. The
present study shows that the AR isoform pattern from AR de novo
synthesis is directly linked to differential phosphorylation of a
distinct set of sites. After mutagenesis of these sites, no major
change in functional activity of the AR was observed.
Key words: androgen receptor, isoform, MS, phosphorylation,
reversed-phase HPLC, transactivation.
INTRODUCTION
The AR (androgen receptor) is a ligand-dependent transcription
factor belonging to the family of steroid hormone receptors.
Similar to other members of the steroid hormone receptor family
including the oestrogen receptor, progesterone receptor, gluco-
corticoid receptor and mineralocorticoid receptor, the AR be-
comes activated after ligand binding. This results in stabilization,
a conformational change and tight nuclear binding of the receptor
and, eventually, in a positive and/or negative transcription regu-
lation of target genes.
Ligand binding is not the only regulatory event in the functions
of steroid hormone receptors. Post-translational modification of
steroid hormone receptors by proteins participating in other sig-
nal-transduction pathways plays a role in the regulation as well.
Phosphorylation of oestrogen receptor α influences transactiv-
ation and association with the co-activators p160 and p300/
CBP [CREB (cAMP-response-element-binding protein)-binding
protein] [1–3] or with the co-repressors N-CoR (nuclear receptor
co-repressor) and SMRT (silencing mediator for retinoic acid
receptor and thyroid hormone receptor) [4]. Transactivation of
the glucocorticoid receptor is also regulated by phosphorylation
[5–7]. A hormone-dependent phosphosite in the progesterone
receptors A and B plays a role in receptor degradation [8], trans-
activation [9] and nuclear export [10,11]. Thus phosphorylation
of specific sites in steroid hormone receptors has been shown to
play a role in various processes.
Post-translational modifications such as acetylation and sumoy-
lation have been shown to influence the transactivation potential
of the AR [12,13]. However, it is not clear whether phosphory-
lation has an effect on the properties and activity of the AR.
It has been shown that the AR is a phosphoprotein [14,15]
and extra phosphorylation of the AR is induced when cells are
exposed to androgens, in addition to the so-called basal AR phos-
phorylation observed in the absence of androgens [15,16].
Phosphorylation occurs predominantly at serine residues [16,17],
which are mainly located in the N-terminal domain [18]. Further-
more, phosphorylation is correlated with the three AR isoforms
that appear on an SDS/polyacrylamide gel [19]. Within minutes
after the start of de novo synthesis, the AR appears as a 110 kDa
isoform, whereas generation of the second (112 kDa) isoform
follows within 15 min as shown by radioactive methionine-
labelling studies [20,21]. Only after hormone binding does the
third (114 kDa) isoform appear [19]. The AR isoform pattern is
correlated with AR phosphorylation as was shown in previous
studies by using phosphatases. The dephosphorylation of AR by
phosphatases resulted in the loss of one isoform either in the pre-
sence or absence of hormone [19]. This effect was also observed
when AR phosphosites were mutated [19]. Furthermore, several
phosphorylation sites have been identified. The first identi-
fied phosphosites, Ser-81, Ser-94 and Ser-650, were found by
mutagenesis analyses in combination with SDS/PAGE [19,22].
Ser-308 was the first phosphosite identified by mutagenesis and
MS [23]. Ser-16, Ser-81, Ser-94, Ser-256, Ser-308, Ser-424
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and Ser-650 were all identified and confirmed as phosphosites
by mutagenesis, peptide mapping and MS [16]. However, cell-
free in vitro phosphorylation reaction studies on AR mutants also
demonstrated Ser-213, Ser-515 and Ser-791 to be phosphosites
[24–26].
It is still not clear to what extent phosphorylation is
involved in the appearance of isoforms and which sites in the
different isoforms are phosphorylated. In the present study, phos-
phorylation of the isoforms was further explored by studying
the differential phosphorylation of the three AR isoforms. An
attempt was made to identify all the phosphosites. Furthermore,
the consequences of transcriptional activation of the identified and
potential phosphosites were evaluated using functional assays,
which tested the transactivation, N- and C-terminal-domain in-
teraction and co-activation by TIF2 (transcriptional intermediary
factor 2), and the functional assays were performed in COS-1
and CHO (Chinese-hamster ovary) cell lines and two prostate
cancer cell lines (PC-3 and DU-145). In contrast with a pre-
vious study, which showed that Ser-94 was constitutively phos-
phorylated [16], our study showed that the Ser-650 is con-
stitutively phosphorylated.
MATERIALS AND METHODS
Materials
Phosphate-free DMEM (Dulbecco’s modified Eagle’s medium)
and goat anti-mouse agarose beads were purchased from Sigma–
Aldrich (St. Louis, MO, U.S.A.). Media (GlutaMAX I-supple-
mented DMEM/F12 and RPMI 1640) and filtertop culture flasks
were purchased from Invitrogen (Paisley, U.K.). Multiwell tissue
culture plates were obtained from Nunc (Roskilde, Denmark).
FCS (fetal calf serum) was obtained from Greiner (Frickenhausen,
Germany) and the mixture of penicillin and streptomycin was
from BioWhittaker (Walkersville, MD, U.S.A.). The oligonucleo-
tides used in plasmid construction and sequencing were syn-
thesized by Eurogentec (Liege, Belgium). FuGENE 6, Complete
inhibitor EDTA-free, shrimp alkaline phosphatase and Rapid
DNA Ligation kits were obtained from Roche (Basel,
Switzerland) and Quik Change Site-Directed Mutagenesis kit was
from Stratagene (La Jolla, CA, U.S.A.). Steady-Glo Luciferase
assay system and sequencing-grade modified trypsin (specific
activity, 16 000 units/mg) were obtained from Promega (Madison,
WI, U.S.A.). [32P]Pi was from Amersham Biosciences (Uppsala,
Sweden). F39.4.1 is a mouse monoclonal antibody raised against
amino acids 301–320 of the human AR [27] and SP197 is
a rabbit polyclonal antibody [18]. The 10× Tris/glycine/SDS
electrophoresis buffer and N,N,N ′,N ′-tetramethylethylenediamine
were obtained from Bio-Rad Laboratories (Hercules, CA,
U.S.A.). HPLC reagents were of sequencing grade and obtained
from Merck (Darmstadt, Germany). Deltapack C18 column was
purchased from Waters and C-18 Z-tips were from Millipore
(Milford, MA, U.S.A.). NEN Life Science Products (Boston, MA,
U.S.A.) supplied R1881 (methyltrienolone). MMTV-Luc reporter
plasmid (where MMTV stands for murine-mammary-tumour
virus) was kindly provided by Dr R. Dijkema (Organon, Oss, The
Netherlands) and has been described previously [28]. SpeedVac
concentrator was obtained from Thermo Savant (Division of
Thermo Electron Corporation, Waltham, MA, U.S.A.).
Plasmid construction
Plasmid construction was performed according to standard
methods [29] and, where indicated, the plasmids were rendered
blunt-ended with Klenow. Constructs including a PCR-ampli-
fication step for preparation were sequenced to verify the correct
reading frame and the absence of random mutations. All the AR
amino acid numbers used in the present study are based on the
National Center for Biotechnology Information accession number
AAA51729, which refers to the AR consisting of 919 amino acids
[30]. The mutants AR S650A (Ser-650 → Ala) and AR S515A
were constructed by site-directed mutagenesis using PCR DNA
amplification techniques. The following sense oligos were used
for introducing the substitution with a Quik Change: AR S650A,
5′-CCAGCACCACCGCCCCCACTGAG-3′; and AR S515A, 5′-
CCTATCCCGCTCCCACTTGT-3′. The mutations are indicated
in italics and underlined. AR104 was described previously as
pSVAR-104, which is the AR construct containing sequences
encoding the C-terminal amino acids 537–919 [31]. The N-ter-
minal construct, pSVAR(TAD1-494), consists of the AR amino
acids 1–503 [32]. AR104/S650A was prepared by the digestion of
BHEXARS650A with SacI and ligating the fragment into AR104
by using the Rapid DNA Ligation kit. TIF2 is described as a
co-activator in [33,34].
COS-1 cell culture, transfection, metabolic labelling
with [32P]Pi and immunoprecipitation
COS-1 cells were cultured in DMEM/F12 supplemented with
GlutaMAX I and 5% (v/v) FCS treated with dextran-coated
charcoal (dcc-FCS). For steady-state labelling, 1.5 × 106 COS-1
cells were grown overnight in an 80 cm2 flask with 8 ml of
DMEM/F12, followed by transfection with the following mix:
4 µg of the indicated plasmid with 12 µl of FuGENE 6 trans-
fection reagent in 200 µl of serum- and antibiotics-free DMEM/
F12. Transfections were performed according to the manu-
facturer’s instructions for FuGENE 6. After 30 h, cells were
washed twice with 0.9% (w/v) NaCl and incubated in phosphate-
free DMEM, supplemented with 50 mM Hepes buffer and 5%
dcc-FCS, which had been dialysed for 24 h against 0.9% NaCl.
Subsequently, cells were incubated with R1881 as indicated
and [32P]Pi (0.333 mCi/ml) for 16 h. Cells were harvested and
lysed at 4 ◦C in immunoprecipitation buffer A [40 mM Tris/
HCl (pH 7.4), 5 mM EDTA (pH 8.0), 10% (v/v) glycerol,
10 mM sodium phosphate, 10 mM sodium molybdate, 50 mM
sodium fluoride, 0.5 mM sodium orthovanadate, 0.6 mM PMSF,
0.5 mM Bacitracin, Complete inhibitor EDTA-free and 10 mM
dithiothreitol], supplemented with 1% (v/v) Triton X-100, 0.5%
(w/v) deoxycholic acid and 0.08% (w/v) SDS. Subsequently,
the lysate was centrifuged at 100 000 g for 30 min at 4 ◦C. The
supernatant was then incubated at 4 ◦C with the antibody F39.4.1,
which was linked to goat anti-mouse agarose. After 2 h, the
agarose beads were washed as follows: three times with buffer A
supplemented with 1% Triton X-100, 0.5% deoxycholic acid
and 0.08% SDS, three times with buffer A supplemented with
0.2%Triton X-100 and 0.4 M NaCl and three times with buffer A
without any additions. The immunoprecipitated AR was separated
by SDS/PAGE (7% gel). After fixing the gel in 10% (v/v) acetic
acid and 50% (v/v) methanol, the gel was subjected to Coomassie
Blue staining and destaining. Subsequently, the AR band was
excised from the gel and digested with sequencing-grade modified
trypsin.
In-gel digestion and RP (reversed-phase) HPLC analysis
The excised AR spot was in-gel-digested as described by
Shevchenko et al. [35] with 20 units of sequencing-grade modified
trypsin for 16 h at 37 ◦C. The amount of trypsin necessary to
secure full digestion of the higher amount of AR protein in the pre-
sence of hormone was verified by varying the amount. The
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peptides were extracted as described by Shevchenko et al. [35]
and dried in a SpeedVac for 1.5 h. The peptides were dissolved
in 0.1% (v/v) trifluoroacetic acid. Then, 25 µl of this solution
was applied to a 2 mm × 150 mm Waters Deltapack C18 column.
The flow was set to 0.18 ml/min and fractions were collected
every 1.5 min until a gradient of 18% (v/v) acetonitrile in 0.1%
trifluoroacetic acid was reached.
Peptide gel
A 40% (w/v) acrylamide alkaline peptide gel was cast and run as
described by West et al. [36].
Characterization of the HPLC fractions with MS
AR tryptic peptides were separated by RP-HPLC. The fractions
with retention times corresponding to 32P-labelled tryptic phos-
phopeptides were collected and, after drying in a SpeedVac,
they were dissolved in 20 µl of 50% acetonitrile. With electro-
spray ionization MS and MS/MS, data were collected from the
individual fractions using a Q-TOF (Micromass, Wythenshaw,
Manchester, U.K.). The peptides were directly infused in the
Q-TOF with a nanospray needle (Micromass) containing a 3 µl
sample plus 0.3 µl of 10% (v/v) formic acid. Low-energy col-
lision-induced dissociation of selected precursor ions was used
to obtain fragmentation spectra. These were deconvoluted
(Masslynx software; Micromass) and used to identify the cor-
responding tryptic peptides, including modifications, of the AR.
CHO, PC-3, DU-145 and COS-1 cell culture, transfection
and luciferase assay
CHO and COS-1 cells were maintained in DMEM/F12 culture
medium, supplemented with 5% dcc-FCS. PC-3 and DU-145
were cultured in RPMI 1640 medium, supplemented with 5%
FCS. For transcription activation experiments, the cells were
plated in 24-well plates at a density of 2 × 104 cells/well (1.9 cm2)
in 500 µl of either DMEM/F12 or RPMI 1640 and grown over-
night. Cells were transfected using 100 µl of either serum- and
antibiotics-free DMEM/F12 or RPMI 1640 containing FuGENE
6 (FuGENE/DNA ratio of 3:1) with AR expression plasmids and,
where indicated, with TIF2 reporter plasmids (50 ng/well)
and pTZ19 carrier plasmid to a total DNA concentration of
250 ng/well. After 5 h, R1881 was added, followed by an over-
night incubation; at the end of this incubation, the cells were
harvested for a luciferase assay. Then, 50 µl of lysis buffer
[25 mM Tris/phosphate (pH 7.8), 15% glycerol, 1% Triton
X-100, 8 mM MgCl and 1 mM dithiothreitol] was added to the
cells. After incubation for 10 min, 25 µl of the supernatants
were transferred to white non-transparent 96-well assay plates,
and 25 µl of 16 mg Steady-Glo Luciferase assay substrate per
ml of Steady-Glo luciferase assay buffer was added. Luciferase
activity was measured with a TopCount luminometer (Packard
Bioscience, PerkinElmer Life Sciences, Zaventem, Belgium).
Western blotting
COS-1 cells were plated at a density of 1 × 106 cells/80 cm2 flask
and transfected with 4 µg of AR expression plasmid and 12 µl
of FuGENE. After an overnight incubation with hormones, the
cells were washed once with PBS, and immunoprecipitation
buffer (see the COS-1 cell culture subsection), supplemented
with protease inhibitors, was added. Lysates were centrifuged for
10 min at 400 000 g and AR was immunoprecipitated with the
monoclonal antibody F39.4.1. Next, samples were subjected to
Figure 1 AR isoforms on a Coomassie Blue-stained SDS/polyacrylamide
gel
WT AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the absence or presence
of 10 nM R1881 for 16 h. The same amount of total lysate of the two conditions was used
for AR immunoprecipitation with the monoclonal antibody F39.4.1. The immunoprecipitated
AR was separated by SDS/PAGE (7 % gel) and Coomassie Blue-stained (A) or blotted and
immunostained with the polyclonal antibody SP197 (B). The corresponding autoradiogram is
also shown in (B).
SDS/PAGE and blotted on to a nitrocellulose membrane. AR
was immunoblotted with the AR polyclonal antibody SP197
and visualized by chemiluminescence detection or by using an
alkaline phosphatase-conjugated secondary antibody.
RESULTS
AR isoform expression
To verify the AR isoform pattern on an SDS/polyacrylamide gel,
WT (wild-type) human AR was expressed by transient trans-
fection into COS-1 cells and metabolically labelled with [32P]Pi
either in the absence or presence of the synthetic androgen R1881.
The same amount of total lysate of the two conditions was used
for AR immunoprecipitation. After immunopurification, the gel
was stained with Coomassie Blue. In the absence of R1881, the
two isoforms (110 and 112 kDa) were clearly visible and the pre-
sence of R1881 resulted in the appearance of the third isoform of
114 kDa (Figure 1A).
Lysates obtained by the same procedure as the previous experi-
ment were also immunoprecipitated and blotted. The immunoblot
showed the same isoform pattern (Figure 1B) as the Coomassie
Blue-stained gel. An autoradiogram of the corresponding im-
munoblot showed an upshift of a phosphorylated band and an
increase in phosphorylation (Figure 1B). This increase is partly
due to stabilization of the AR. These results confirm that the AR is
phosphorylated in the absence of hormone and that phosphoryl-
ation of the AR is increased in the presence of hormone [16].
Furthermore, this suggests that the upshift of a phosphorylated
band corresponds to the 114 kDa isoform.
Changes in AR phosphorylation induced by R1881
To investigate whether androgenic activation increases the phos-
phorylation of existing phosphosites and/or induces phosphoryl-
ation of new sites, the AR was expressed by transient transfection
into COS-1 cells and metabolically labelled with [32P]Pi either in
c© 2004 Biochemical Society
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Figure 2 R1881-induced changes in AR phosphorylation pattern
AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the absence (A) or
presence (B) of 10 nM R1881. The same amount of total lysate of the two conditions was
used for AR immunoprecipitation (with anti-AR monoclonal antibody F39.4.1). The precipitated
AR was digested with trypsin and the peptides obtained were separated on an RP HPLC C18
column. HPLC fractions were collected and the amount of [32P]Pi incorporated was determined.
The different radioactive fractions are indicated with A–F. Note that the ordinates have a different
scale.
the absence or presence of R1881. After immunopurification and
subsequent digestion with trypsin, the resulting peptides were
separated on an RP HPLC column. The RP HPLC elution pattern
of AR in absence of R1881 showed that several fractions contained
32P-labelled peptides (Figure 2A, fractions A, B, D and E). After
stimulating the cells with 10 nM R1881, an increase in phos-
phorylation of the peptides in fractions A, B, D and E was observed
(Figure 2B). In addition, the relative phosphorylation level of two
peptides in fractions C and F was slightly increased (Figure 2B).
It is important to note that the overall phosphorylation pattern was
highly reproducible in ten independent experiments. These results
are in agreement with a previous report that hormone binding
results in increased phosphorylation of existing phosphorylated
sites [16].
Differential phosphorylation of AR isoforms
To study differential phosphorylation of the three isoforms of 110,
112 and 114 kDa in more detail, COS-1 cells were transfected
with AR and stimulated for 16 h with R1881 and labelled with
[32P]Pi. Each 32P-labelled AR isoform was isolated separately
from an SDS/polyacrylamide gel. The phosphorylation pattern
of tryptic fragments of the individual isoforms revealed that the
110 kDa isoform is predominantly phosphorylated on the peptide
in fraction D (Figure 3A). The phosphorylation level of fraction
Figure 3 Differential phosphorylation of AR isoforms
AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the presence of
10 nM R1881. AR was immunoprecipitated (with anti-AR monoclonal antibody F39.4.1) and the
isoforms of 110 kDa (A), 112 kDa (B) and 114 kDa (C) were separately cut out from the same
lane on an SDS/7 % polyacrylamide gel followed by trypsin digestion. The peptides obtained
were separated on an RP HPLC column. HPLC fractions were collected and the amount of [32P]Pi
incorporated was determined. The different radioactive fractions are indicated with A–F.
D in the 112 kDa isoform was similar to that in the 110 kDa iso-
form (Figures 3A and 3B) and slightly increased further in the
114 kDa isoform (Figure 3C). Since fraction D contains the pep-
tide with the phosphorylated Ser-650 (see below), these results
indicate that Ser-650 is constitutively phosphorylated.
The phosphorylation level of the different RP HPLC fractions
for each isoform was found to be different and to get an impression
of quantitative changes, the fold increase has been calculated.
First, the phosphorylation level of each peptide is based on the
sum of the radioactivities in three consecutive fractions. Since
phosphorylation of fraction D was shown to be more or less
c© 2004 Biochemical Society
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Table 1 Phosphorylation ratios of AR peptides
The phosphorylation ratio of different fractions is calculated relative to the intensity of phosphorylation of fraction D (1.0, see also text).
Phosphorylation
HPLC fractions Fraction X/D (110 kDa isoform) Fraction X/D (112 kDa isoform) Fold increase (relative to 110 kDa) Fraction X/D (114 kDa isoform) Fold increase (relative to 110 kDa)
A 0.3 0.8 2.9 1.4 5.1
B 0.2 0.4 1.9 0.9 4.3
C 0.1 0.1 0.7 0.2 1.3
D 1.0 1.0 1.0 1.0 1.0
E 0.3 0.3 1.0 0.4 1.2
F 0.1 0.1 1.1 0.2 2.9
Figure 4 Separation of individual HPLC fractions on a 40% acrylamide
alkaline peptide gel
Peptides from HPLC fractions were separated on a 40 % acrylamide alkaline peptide gel. Note
that the separation is according to size and charge. Phosphopeptides were visualized by using
a PhosphorImager (Molecular Dynamics). The different radioactive fractions are indicated with
A, B, D and E.
constant in the different isoforms, the level of phosphorylation
in the other fractions was calculated relative to the level of phos-
phorylation in fraction D. Furthermore, the change in ratios for the
112 and 114 kDa isoforms were calculated relative to the ratios
for the 110 kDa isoform, resulting in fold increase (Table 1). The
fold increase of the fractions A, B, C, E and F obtained from
the 110 kDa isoform were low. For the 112 kDa isoform, the fold
increase of fractions A and B was 2–3-fold higher (Table 1). The
fold increase of fractions C, E and F was the same in the 112 kDa
isoform compared with the 110 kDa isoform.
Moreover, analysis of the 114 kDa isoform showed that, in the
presence of R1881, the fold increase of fractions C and E was
rather small, but the fold increase of phosphorylation in frac-
tions A, B and F were higher (Table 1). These results confirm that
a correlation exists between phosphorylation status and the SDS/
PAGE migration pattern for the three AR isoforms [19]. In conclu-
sion, increase in phosphorylation is correlated with a decreased
migration rate.
Phosphopeptide analysis
To characterize the HPLC fractions in more detail, the most
intensely phosphorylated fractions (A, B, D and E) were sub-
jected to further analysis on a 40% acrylamide alkaline peptide
gel. Peptide analysis revealed that fractions A, D and E each
contained a single phosphorylated peptide and that each peptide
was different from the others (Figure 4). However, fraction B con-
tained two phosphorylated peptides. The peptide in fraction B,
which migrated into the gel as far as the peptide in fraction A, is
most probably identical with the phosphorylated peptide from
fraction A and is present in fraction B due to incomplete resolution
during HPLC separation. These data show that at least four
different peptides derived from the AR are phosphorylated.
Peptide analysis by MS
To identify the phosphorylated amino acid residues, MS analysis
was used to characterize first the phosphorylated peptides in
the HPLC fractions. Out of the six HPLC fractions collected
(fractions A–F), five contained tryptic peptides from the AR
(Table 2). The identified peptides in fractions B, D and E were
Table 2 MS data of phosphorylated peptides in RP HPLC fractions
Fraction Measured mass Tryptic peptide fragment* AR peptide Putative phosphosite Prediction†
A 962.4 T70–T71 Cys-852 with acrylamide adduct 847–854 Ser-851 0.962
B 2056.8 T7–T8 plus phosphate probably on Ser-94 84–100 Ser-94 0.572
C n.d.‡
D 2232.0 T50 plus phosphate probably on Ser-647 639–658 Ser-647 0.760
or Ser-650 Ser-650 0.997
E 1226.6 T28 plus phosphate probably on Ser-515; 511–520 Ser-515 0.967
Cys-518 with carbamidomethyl
F 1554.7 T15 221–235 §
* Peptide identification is based on comparison of the detected mass and the corresponding MS/MS information of the measured peptides with all possible tryptic fragments (T1–T79).
† NetPhos 2.0 [40] was used to search for possible phosphorylation sites. A prediction of 0.5 and higher was considered as representing a potential phosphorylation site.
‡ n.d., not determined.
§ No potential phospho-serine residue was present in the peptide.
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phosphorylated. The theoretical mass of these peptides was in-
creased by the mass of one phosphate group (79.9799 Da) and,
moreover, MS/MS data confirmed the presence of this modifi-
cation, probably on a serine residue. The MS/MS data from
fraction D could not discriminate between two possible serine
phosphosites (Ser-647 and Ser-650). Both of the identified tryptic
AR peptides in fractions A and F contained a serine residue, but
were not phosphorylated. The results are summarized in Table 2
together with information on possible putative phosphosites.
A small number of the fractions displayed a variable low level
of phosphorylation, most probably due to contaminations, and
were excluded from further analyses.
Phosphosite identification by site-directed mutagenesis
The peptide in fraction D (amino acid residues 639–658) con-
tains two potential phosphorylation sites, Ser-647 and Ser-650
(Table 2). Substitution of Ser-650 with an alanine residue resulted
in the disappearance of peptide phosphorylation in fraction D
(Figure 5A). In contrast, substitution of Ser-647 to Ala-647 did not
result in any change in phosphorylation (results not shown). This
substantiates the observation that fraction D contains the peptide
consisting of amino acids 639–658 and shows that Ser-650, but
not Ser-647, is a phosphorylation site. Another peptide identified
by MS and consisting of amino acid residues 84–100 (fraction B)
contains the potential phosphosite Ser-94 (Table 2). Substitution
of Ser-94 to Ala-94 resulted in a 40% loss of radioactive phos-
phate incorporation in both fractions A and B (Figure 5B and
Table 3). A third phosphorylated peptide identified in these
experiments is the peptide from fraction E consisting of amino
acid residues 511–520 and containing the potential phosphosite
Ser-515. Remarkably, substitution of Ser-515 to Ala-515 did
not result in disappearance of radioactivity from fraction E. In
contrast, fraction D, which contained the peptide with phosphosite
Ser-650, was no longer radioactive after the Ser-515 to Ala-515
substitution (Figure 5C). This result indicates that changes in
Ser-515 might exert an influence on the phosphorylation status
of Ser-650. In fraction A, the peptide consisting of amino acids
847–854 has the predicted phosphosite Ser-851. Substitution of
Ser-851 with an alanine residue did not result in a change in the
phosphorylation pattern (results not shown). This indicates that
the identified peptide consisting of amino acids 847–854 present
in fraction A does not contain the predicted Ser-851 phosphosite.
No phosphosites were predicted for the identified peptide present
in fraction F and no peptides could be detected in fraction C.
Phosphorylation and AR transcriptional activity
Since the phosphorylation level of the AR was changed in the
presence of R1881, AR phosphorylation might regulate the func-
tional activity of the AR. The transactivation activity of AR
mutants S515A, S650A and S94A was tested using an MMTV-
Luciferase reporter assay in CHO cells. Substitution of Ser-650
to Ala-650 did not result in a change in transactivation of the
MMTV-Luc reporter gene when compared with the WT AR
(Figure 6A). The same neutral effect was found for the S515A
and S94A mutants (results not shown). To exclude the possibility
that CHO cells exert AR phosphorylation in a peculiar cell-type-
specific manner, the same experiment was performed in COS-1
as well as PC-3 and DU-145 cells (both prostate cancer cell lines).
No differences in AR transactivation activity for the three AR
mutants could be detected in any of these three cell lines (results
not shown). These results indicate that loss of AR phosphorylation
on Ser-650, Ser-515 and Ser-94 does not have an effect on AR
transactivation activity.
Figure 5 AR phosphorylation on Ser-650 and Ser-94 and the phosphoryl-
ation influenced by Ser-515
The AR mutant S650A (A), S94A (B) or S515A (C) was expressed in COS-1 cells and labelled
with [32P]Pi for 16 h in the presence of 10 nM R1881. The AR mutant was immunoprecipi-
tated (with anti-AR monoclonal antibody F39.4.1) and digested with trypsin. The peptides
obtained were separated on an RP HPLC C18 column. HPLC fractions were collected and the
amount of [32P]Pi incorporated was determined.
Table 3 Phosphorylation of S94A mutant
The phosphorylation of peptides in fractions A and B from the WT AR (Figure 2B) and the S94A
mutant (Figure 5B) were normalized to their corresponding fractions D. Percentage change in
phosphorylation between the mutant and WT for fractions A and B was calculated from the ratios.
Phosphorylation
Ratio WT AR Mutant S94A Change in phosphorylation (%)
A/D 0.65 0.38 − 42
B/D 0.42 0.23 − 44
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Figure 6 Functional studies on WT AR and the AR mutant S650A
CHO cells were transfected with 50 ng of reporter construct MMTV-Luc, different amounts of DNA
plasmids from either the AR or AR mutant S650A (A), C-terminal construct AR104 or C-terminal
mutant construct AR104/S650A together with 10 ng of N-terminal construct pSVAR(TAD1-494)
(B) or 100 ng of TIF2 cDNA (C). The cells were harvested 16 h after treatment with ethanol or
1 nM R1881. Fold induction is shown at the top of each bar and represents the ratio of activity
determined after incubation in the presence or absence of R1881.
The AR protein can undergo conformational changes resulting
in intra-molecular interaction between the N- and C-terminal
domains [32,37] and this N- and C-terminal interaction can be in-
fluenced by several mutations in the AR, resulting in altered trans-
criptional activation activity of the AR [38,39]. To examine
whether phosphorylation exerts an influence on this interaction,
the C-terminal-domain construct containing the S650A mutant
and the N-terminal-domain construct were co-transfected in CHO
cells. As shown in Figure 6(B), the S650A mutant displayed a
similar functional N- and C-terminal interaction as the WT AR
C-terminal construct.
To investigate whether phosphorylation has an influence on
TIF2 co-activation, CHO cells were co-transfected with constructs
of AR C-terminal domain with or without the S650A substitution
and TIF2. The mutant showed a similar functional interaction
with TIF2 as the WT AR C-terminal domain (Figure 6C).
Figure 7 Immunoblot of S650A and S515A AR mutant isoforms
AR S650A and S515A mutants were expressed in COS-1 cells in the absence or presence of
10 nM R1881 for 16 h. The AR mutants were immunoprecipitated with the monoclonal antibody
F39.4.1, separated by SDS/PAGE (7 % gel), blotted and immunostained with the polyclonal
antibody SP197.
AR isoforms on SDS/PAGE
It has been shown that substitution of the phosphosite Ser-94
by an alanine residue results in a loss of isoforms both in the
absence and presence of hormone [19]. To determine whether
there is a change in isoform pattern of the AR mutants S650A
and S515A, these mutants were expressed in COS-1 cells and
immunoprecipitated. The precipitated AR mutants were separated
by SDS/PAGE. The isoform patterns of both mutants were similar
to the WT AR (Figure 7). Both mutants expressed two isoforms
in the absence of hormone and three isoforms in the presence of
R1881. This indicates that Ser-515 and Ser-650 are not essential
for the migration of 112 and 114 kDa isoforms in the absence or
presence of R1881. Furthermore, these results demonstrate that
loss of phosphorylation on certain sites does not always result in
a change in isoform pattern.
DISCUSSION
The present study shows that the AR isoform pattern after AR
de novo synthesis is directly linked to differential phosphoryl-
ation. It appeared that, after synthesis, the AR 110 kDa isoform
is predominantly phosphorylated at Ser-650, and there is a higher
phosphorylation level for other existing sites in the 112 and
114 kDa isoforms. These results reveal that Ser-650 is consti-
tutively phosphorylated. Moreover, loss of phosphorylation on
certain sites does not always result in a change in isoform pattern.
Functional analysis of the identified phosphosites Ser-94, Ser-650
and Ser-515 revealed that substitution of these sites with alanine
does not influence AR function.
Recently, several AR phosphosites were identified after transi-
ent expression in COS-1 cells, by sequencing AR peptides using
tandem MS and Edmann degradation [16]. Our approach was
different, i.e. RP HPLC was used instead of two-dimensional thin-
layer electrophoresis and ascending chromatography. With the
purified fractions of the tryptic peptides containing possible phos-
phosites, tandem MS can be a good tool for identification.
However, it is not always possible to identify the exact position of
the phosphate group. Fragmentation data may lack the specific
fragment ions containing the phosphate group owing to the
individual fragmentation behaviour of the peptide or by loss of
their positive charges during the collision-induced dissociation.
Although all fractions contained radioactivity, only three phos-
phopeptides could be identified. A possible explanation is that
the concentration of the peptides containing the phosphate group
is too low or the peptides containing the phosphate group are
not easily ionized with electrospray. MS is a valuable tool, but
additional information, such as site-directed mutagenesis in this
case, is necessary.
The autoradiogram and the HPLC elution pattern revealed that
the phosphorylation was increased approx. ten times. A previous
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study showed that hormone binding results in an increased phos-
phorylation of existing phosphorylated sites by approx. 1.8 times
[15]. This indicates that the apparent extra phosphorylation of
approx. five times results from stabilization by hormone binding.
The phosphorylation pattern of the isoforms revealed that
Ser-650 is already phosphorylated in the 110 kDa isoform
and Ser-94 in the 112 kDa isoform. However, these phosphoryl-
ation patterns were studied in the presence of R1881, which raises
the question whether Ser-650 is phosphorylated in the 110 kDa
isoform and Ser-94 in the 112 kDa isoform in the absence of
R1881 as well. However, the RP HPLC elution pattern of the AR
in the absence of R1881 also showed the presence of phosphoryl-
ation in fractions A, B and D (Ser-94 and Ser-650; Figure 2A). It
is therefore probable that the phosphorylation pattern of the 110
and 112 kDa isoforms in absence of R1881 is the same as that in
the presence of R1881. Moreover, this suggests that phosphoryl-
ation of fraction D in the 110 kDa isoform and phosphorylation
of fractions A and B in the 112 kDa isoform are not hormone-
induced.
Surprisingly, site-directed mutagenesis of the Ser-515 to an
alanine residue revealed dephosphorylation of a totally different
site, Ser-650. This type of distal influence on phosphorylation
caused by the substitution of another site has been observed by
others [16]. Gioeli et al. [16] suggested that substitution of Ser-424
with an alanine residue resulted either in the mobility shift of
a phosphorylated peptide or in phosphorylation of new sites.
In the present study, the dephosphorylation of Ser-650 induced
by the S515A substitution might be due to a conformational
change, which resulted in a surface more accessible for phospha-
tases or less accessible to kinases. Interestingly, both sites are
flanking the DNA-binding domain and are located in flexible
regions of the AR protein.
The reason why substitution of Ser-515 with an alanine residue
does not result in the disappearance of phosphorylation in frac-
tion E might be that other serine residues in this peptide are phos-
phorylated as well. Although these serine sites are not predicted
as potential phosphosites by NetPhos [40], it predicts that
Tyr-513 is a phosphorylation consensus site [40]; however, two-
dimensional phosphopeptide mapping studies have shown that
only serine residues in the AR are phosphorylated [16,17]. Sub-
stitution of Ser-94 with an alanine residue resulted in a partial
decrease in phosphorylation level (40%) in fractions A and B.
This suggests that one phosphopeptide of the two in fraction B as
seen on the peptide gel was identical with a peptide with the same
mass and charge in fraction A. In addition, this also suggests that
there might be another peptide present in both fractions. Alternat-
ively, the presence of a partially digested peptide containing
Ser-94 is excluded. The partially digested peptide would consist
of amino acids 41–99 and contains the identified phosphosite
Ser-81 [16]. However, the peptide will be very large and, therefore,
difficult to elute from an SDS/polyacrylamide gel. Furthermore,
the presence of two phosphopeptides only in fraction B and not
in fraction A is in favour of a complete digestion.
Substitution of Ser-851 with an alanine residue did not result
in the disappearance of radioactive phosphate in fraction A.
Partial digestion of AR, resulting in a peptide containing Ser-851
and another potential phosphorylation site, is unlikely, since this
would result in a very large peptide that cannot be eluted from
a gel. Substitution of Ser-851 did not result in a change of phos-
phorylation in fraction A or other fractions (results not shown),
which indicates that Ser-851 is not a phosphosite at all. The
presence of another phosphopeptide cannot be excluded.
A change in AR phosphorylation appears to have no prominent
function in AR transactivation. Similar findings were reported
by Gioeli et al. [16] by using the PSA-Luc reporter construct in
CV1 cells. In contrast, Zhou et al. [22] showed a decreased trans-
activation of the mutant S650A of 10–30% on the MMTV-Luc
reporter also in CV1 cells.
It appears that phosphorylation does not play a major role in
hormone-induced AR N- and C-terminal interaction or TIF2 co-
activation, although it cannot be excluded that the cellular context
as well as the reporter construct could influence this activity and
that other so far unidentified phosphosites are involved [41].
After AR de novo synthesis, the 110 kDa isoform became
immediately and predominantly phosphorylated on Ser-650. The
112 kDa isoform displayed an additional phosphorylation of
Ser-94 and another peptide in fractions A and B only. The
relationship between phosphorylation of Ser-94 and the appear-
ance of the 112 kDa isoform corresponds to an immunoblot study
in which S94A caused disappearance of the 112 kDa isoform in
the absence of hormone and disappearance of the 114 kDa isoform
in the presence of hormone [19].
In contrast with S94A AR mutant, substitution of Ser-650 with
an alanine residue does not influence the isoform pattern on SDS/
PAGE, which is understandable because Ser-650 phosphorylation
occurs already in the 110 kDa isoform and is unchanged in the
112 kDa isoform and slightly changed in the 114 kDa isoform.
The Ser-650 site represents basal phosphorylation of the AR
and only changes in phosphorylation of other sites could perhaps
contribute to the appearance of the isoforms. Substitution of the
phosphosite Ser-81 to a glycine residue resulted in the loss of
the largest isoform irrespective of the presence of ligand [19].
Similar results were obtained for the double-mutant S81/94A
[22]. However, substitution of Ser-81 with an alanine residue
resulted in the loss of one isoform only in the presence of hormone
(results not shown). The RP HPLC elution pattern of the three
isoforms illustrated the correlation between the phosphorylation
status of sites other than Ser-650 and the migration pattern of the
three AR isoforms during SDS/PAGE. Phosphorylation does not
necessarily contribute to the appearance of isoform as shown by
the mutant S650A.
The appearance of the 114 kDa isoform induced by R1881 is
directly linked to an overall increase in phosphorylation of several
sites as compared with the 110 and 112 kDa isoforms. This overall
increase in phosphorylation was shown previously by van Laar
et al. [15] and Gioeli et al. [16]. However, newly phosphorylated
sites could not be identified. It is quite probable that these sites
are important for the hormone-regulated transactivation of the
AR, because their phosphorylation is linked to DNA-binding and
transcription activation. Furthermore, these phosphorylation sites
could be target sites for AR activation via crosstalk with other sig-
nal transduction pathways as well. Thus identifying the kinase(s)
involved in the phosphorylation of these sites and the possible
signalling pathway will be useful to elucidate the mechanisms of
ligand-independent activation of the AR.
There are several kinases predicted to be involved in the
phosphorylation of AR. The identified phosphosites Ser-94 and
Ser-650 are so-called Ser-Pro sites, which can be phosphorylated
by serine-proline-directed kinases (Ser/Thr-Pro), MAPK (mito-
gen-activated protein kinase) and cyclin-dependent kinases such
as Cdc2 and Cdks. In addition, Ser-650 is a specific consensus site
for casein kinases 1 and 2. There are conflicting data concerning
which kinases phosphorylate the AR. It has been shown that pro-
tein kinase C [16,28], MAPK and AKT kinase [16] have no in-
fluence on the phosphorylation of the AR. However, other in vitro
kinase studies showed that AKT [24,25] is capable of phos-
phorylating the AR. Furthermore, MAPK was also a candidate
protein kinase of the AR [26]. However, in that particular study,
the phosphorylation status of the MAPK site S515A AR mutant
was not investigated [26].
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Although basal phosphorylation of the AR does not seem to
have a function, it is quite probable that a hormone-regulated
phosphorylation of the AR is associated with transcriptional activ-
ation. Identification of the hormone-induced AR phosphorylation
sites and subsequent elucidation of their possible function by
mutational analysis in vivo could contribute significantly to our
understanding of the mechanism of androgen action. Furthermore,
it could reveal new targets for intervention in androgen action in
prostate cancer.
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